|
|
Vaccine Detail
|
Mammaglobin-A DNA Vaccine |
| Vaccine Information |
- Vaccine Name: Mammaglobin-A DNA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007398
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CEACAM1
gene engineering:
- Type: Recombinant protein preparation
- Description: (Kim et al., 2016)
- Detailed Gene Information: Click Here.
- MUC1
gene engineering:
- Type: Recombinant protein preparation
- Description: (Kim et al., 2016)
- Detailed Gene Information: Click Here.
- ERBB2
gene engineering:
- Type: Recombinant protein preparation
- Description: (Kim et al., 2016)
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine containing a plasmid encoding the mammaglobin-A gene with potential immunostimulating and antineoplastic activities. Upon administration, mammaglobin-A DNA vaccine may induce both humoral and cytotoxic T lymphocyte (CTL) immune responses against tumor cells that express mammaglobin-A, which may result in decreased tumor growth. The 10 kiloDalton (kD) glycoprotein mammglobin-A is expressed in over 80% of human breast cancers. (NCIT_C82675).
|
| Host Response |
|
|
| References |
Kim et al., 2016: Kim SW, Goedegebuure P, Gillanders WE. Mammaglobin-A is a target for breast cancer vaccination. Oncoimmunology. 2016; 5(2); e1069940. [PubMed: 27057470].
NCIT_C82675: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82675]
|
|
